688098.SH
Shanghai Shen Lian Biomedical Corp.
SSE · Healthcare · Biotechnology · CN
CNY 8.00
−3.03%Sep 20, 2026, 07:31 UTC
Shenlian Biotech's controlled subsidiary Shizhiyuan announced that its biologic drug UB-221 injection met the primary endpoint in a Phase II clinical trial for chronic spontaneous urticaria, with positive topline results in 145 patients.
Sep 16, 2026, 09:29 UTC
Shenlian Biotechnology signed a supplementary contract with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other units to add SAT1-type foot-and-mouth disease antigens for pigs and cattle to their existing multi-valent vaccine co-development contract.
Source:Aug 30, 2026, 07:37 UTC
Shenlian Biotech appointed Gao Xu as deputy general manager, effective from the board meeting date until the end of the fourth board term.
Source:Aug 30, 2026, 07:36 UTC
Shenlian Biologic reported its first-half 2026 results: revenue of 112 million yuan, down 8.05% year-on-year; net loss attributable to shareholders of 19.1464 million yuan, compared with a net loss of 12.8697 million yuan in the same period last year; non-recurring net loss of 19.1558 million yuan; R&D investment accounted for 19.91% of revenue, down 2.41 percentage points year-on-year.
Source: